(STE) STERIS - Ratings and Ratios
Sterilizers, Washers, Disinfectants, Sterilization Services, Surgical Tables
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 1.01% |
| Yield on Cost 5y | 1.32% |
| Yield CAGR 5y | 9.65% |
| Payout Consistency | 94.1% |
| Payout Ratio | 24.3% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 21.5% |
| Value at Risk 5%th | 33.5% |
| Relative Tail Risk | -5.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.74 |
| Alpha | 11.24 |
| CAGR/Max DD | 0.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.492 |
| Beta | 0.527 |
| Beta Downside | 0.507 |
| Drawdowns 3y | |
|---|---|
| Max DD | 19.93% |
| Mean DD | 6.84% |
| Median DD | 5.79% |
Description: STE STERIS December 17, 2025
STERIS plc (NYSE: STE) supplies infection-prevention products and services worldwide through three operating segments. The Healthcare segment delivers cleaning chemistries, endoscope reprocessing systems, sterile-processing equipment, and related capital-equipment services. The Applied Sterilization Technologies (AST) segment offers contract sterilization and testing for medical-device and pharmaceutical makers, plus integrated sterilization equipment. The Life Sciences segment manufactures consumables (e.g., detergents, disinfectants, vaporized-hydrogen-peroxide systems) and high-purity water/steam generators, together with installation and maintenance services. The company serves hospitals, other health-care providers, and pharma manufacturers, and is headquartered in Mentor, Ohio.
Key recent metrics: FY 2023 revenue reached roughly $3.5 billion, up about 6 % YoY, driven by strong demand for endoscope reprocessing solutions as hospitals expand procedural volumes post-COVID-19. Operating margin stabilized near 14 % and cash-conversion remained above 80 %, supporting a growing backlog of ~ $1.2 billion. Sector-wide, the global infection-control market is projected to grow at a CAGR of 7-8 % through 2028, while capital-equipment spending in U.S. hospitals is expected to rise 4 % annually, both of which underpin STE’s growth outlook.
For a deeper, data-driven assessment of STE’s valuation and risk profile, you may find the analysis on ValueRay worth a look.
Piotroski VR‑10 (Strict, 0-10) 9.0
| Net Income: 688.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 2.59 > 1.0 |
| NWC/Revenue: 21.35% < 20% (prev 22.55%; Δ -1.20% < -1%) |
| CFO/TA 0.13 > 3% & CFO 1.30b > Net Income 688.5m |
| Net Debt (1.74b) to EBITDA (1.47b): 1.19 < 3 |
| Current Ratio: 2.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (98.8m) vs 12m ago -0.41% < -2% |
| Gross Margin: 44.29% > 18% (prev 0.43%; Δ 4386 % > 0.5%) |
| Asset Turnover: 55.22% > 50% (prev 49.04%; Δ 6.19% > 0%) |
| Interest Coverage Ratio: 14.60 > 6 (EBITDA TTM 1.47b / Interest Expense TTM 67.0m) |
Altman Z'' 4.43
| A: 0.12 (Total Current Assets 2.11b - Total Current Liabilities 888.9m) / Total Assets 10.41b |
| B: 0.26 (Retained Earnings 2.73b / Total Assets 10.41b) |
| C: 0.09 (EBIT TTM 978.1m / Avg Total Assets 10.33b) |
| D: 2.07 (Book Value of Equity 7.01b / Total Liabilities 3.39b) |
| Altman-Z'' Score: 4.43 = AA |
Beneish M -3.12
| DSRI: 0.90 (Receivables 947.3m/923.3m, Revenue 5.70b/5.02b) |
| GMI: 0.97 (GM 44.29% / 43.00%) |
| AQI: 0.96 (AQ_t 0.58 / AQ_t-1 0.61) |
| SGI: 1.14 (Revenue 5.70b / 5.02b) |
| TATA: -0.06 (NI 688.5m - CFO 1.30b) / TA 10.41b) |
| Beneish M-Score: -3.12 = AA |
ValueRay F-Score (Strict, 0-100) 75.12
| 1. Piotroski: 9.0pt |
| 2. FCF Yield: 3.41% |
| 3. FCF Margin: 16.86% |
| 4. Debt/Equity: 0.29 |
| 5. Debt/Ebitda: 1.19 |
| 6. ROIC - WACC: 1.17% |
| 7. RoE: 10.21% |
| 8. Revenue Trend: 71.43% |
| 9. EPS Trend: 71.65% |
What is the price of STE shares?
Over the past week, the price has changed by -2.74%, over one month by +2.26%, over three months by +7.91% and over the past year by +20.56%.
Is STE a buy, sell or hold?
- Strong Buy: 3
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the STE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 281.6 | 7.9% |
| Analysts Target Price | 281.6 | 7.9% |
| ValueRay Target Price | 284.9 | 9.2% |
STE Fundamental Data Overview January 18, 2026
P/E Forward = 24.0964
P/S = 4.6401
P/B = 3.7564
P/EG = 1.8399
Revenue TTM = 5.70b USD
EBIT TTM = 978.1m USD
EBITDA TTM = 1.47b USD
Long Term Debt = 1.90b USD (from longTermDebt, last quarter)
Short Term Debt = 35.3m USD (from shortTermDebt, last quarter)
Debt = 2.06b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.74b USD (from netDebt column, last quarter)
Enterprise Value = 28.20b USD (26.46b + Debt 2.06b - CCE 319.2m)
Interest Coverage Ratio = 14.60 (Ebit TTM 978.1m / Interest Expense TTM 67.0m)
EV/FCF = 29.34x (Enterprise Value 28.20b / FCF TTM 961.2m)
FCF Yield = 3.41% (FCF TTM 961.2m / Enterprise Value 28.20b)
FCF Margin = 16.86% (FCF TTM 961.2m / Revenue TTM 5.70b)
Net Margin = 12.07% (Net Income TTM 688.5m / Revenue TTM 5.70b)
Gross Margin = 44.29% ((Revenue TTM 5.70b - Cost of Revenue TTM 3.18b) / Revenue TTM)
Gross Margin QoQ = 44.23% (prev 45.14%)
Tobins Q-Ratio = 2.71 (Enterprise Value 28.20b / Total Assets 10.41b)
Interest Expense / Debt = 0.72% (Interest Expense 14.9m / Debt 2.06b)
Taxrate = 23.94% (60.6m / 253.1m)
NOPAT = 743.9m (EBIT 978.1m * (1 - 23.94%))
Current Ratio = 2.37 (Total Current Assets 2.11b / Total Current Liabilities 888.9m)
Debt / Equity = 0.29 (Debt 2.06b / totalStockholderEquity, last quarter 7.01b)
Debt / EBITDA = 1.19 (Net Debt 1.74b / EBITDA 1.47b)
Debt / FCF = 1.81 (Net Debt 1.74b / FCF TTM 961.2m)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.67% (Net Income 688.5m / Total Assets 10.41b)
RoE = 10.21% (Net Income TTM 688.5m / Total Stockholder Equity 6.75b)
RoCE = 11.32% (EBIT 978.1m / Capital Employed (Equity 6.75b + L.T.Debt 1.90b))
RoIC = 8.50% (NOPAT 743.9m / Invested Capital 8.75b)
WACC = 7.33% (E(26.46b)/V(28.52b) * Re(7.86%) + D(2.06b)/V(28.52b) * Rd(0.72%) * (1-Tc(0.24)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF Debug] Terminal Value 83.46% ; FCFF base≈848.8m ; Y1≈1.05b ; Y5≈1.78b
Fair Price DCF = 337.0 (EV 34.82b - Net Debt 1.74b = Equity 33.08b / Shares 98.1m; r=7.33% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 71.65 | EPS CAGR: 4.16% | SUE: 1.35 | # QB: 3
Revenue Correlation: 71.43 | Revenue CAGR: 5.17% | SUE: 0.26 | # QB: 0
EPS current Year (2026-03-31): EPS=10.21 | Chg30d=+0.000 | Revisions Net=+6 | Growth EPS=+9.4% | Growth Revenue=+8.5%
EPS next Year (2027-03-31): EPS=11.13 | Chg30d=+0.000 | Revisions Net=+6 | Growth EPS=+9.1% | Growth Revenue=+6.2%
Additional Sources for STE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle